Human Umbilical Cord–Derived Mesenchymal Stem Cells in the Treatment of Multiple Sclerosis Patients: Phase I/II Dose-Finding Clinical Study
Cell Transplantation · 2024-01 · 33
DOI: 10.1177/09636897241233045 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Cell Transplantation, online erschienen am 07.03.2024. Verfasst von Fatima Jamali und 16 weiteren Autor:innen. Beteiligte Einrichtung: Cell Therapy Center, The University of Jordan, Amman, Jordan. Hauptthemen laut MEDLINE: Multiple Sclerosis, MicroRNAs, Mesenchymal Stem Cells. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Scientific Research Fund, Ministry of Higher Education in the Hashemite Kingdom of Jordan.
Abstract (Originalsprache)
Multiple sclerosis (MS) is a chronic neuro-inflammatory disease resulting in disabilities that negatively impact patients’ life quality. While current treatment options do not reverse the course of the disease, treatment using mesenchymal stromal/stem cells (MSC) is promising. There has yet to be a consensus on the type and dose of MSC to be used in MS. This work aims to study the safety and efficacy of two treatment protocols of MSCs derived from the umbilical cord (UC-MSCs) and their secretome. The study included two groups of MS patients; Group A received two intrathecal doses of UC-MSCs, and Group B received a single dose. Both groups received UC-MSCs conditioned media 3 months post-treatment. Adverse events in the form of a clinical checklist and extensive laboratory tests were performed. Whole transcriptome analysis was performed on patients’ cells at baseline and post-treatment. Results showed that all patients tolerated the cellular therapy without serious adverse events. The general disability scale improved significantly in both groups at 6 months post-treatment. Examining specific aspects of the disease revealed more parameters that improved in Group A compared to Group B patients, including a significant increase in the (CD3 + CD4 + ) expressing lymphocytes at 12 months post-treatment. In addition, better outcomes were noted regarding lesion load, cortical thickness, manual dexterity, and information processing speed. Both protocols impacted the transcriptome of treated participants with genes, transcription factors, and microRNAs (miRNAs) differentially expressed compared to baseline. Inflammation-related and antigen-presenting (HLA-B) genes were downregulated in both groups. In contrast, TNF-alpha, TAP-1, and miR142 were downregulated only in Group A. The data presented indicate that both protocols are safe. Furthermore, it suggests that administering two doses of stem cells can be more beneficial to MS patients. Larger multisite studies should be initiated to further examine similar or higher doses of MSCs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cell Therapy Center, The University of Jordan, Amman, Jordan.
- Department of Physical Therapy, School of Rehabilitation Sciences, The University of Jordan, Amman, Jordan.
- Data Science Department, Princess Sumaya University for Technology, Amman, Jordan.
- Division of Neurology, Department of Internal Medicine, Faculty of Medicine, Jordan University Hospital, The University of Jordan, Amman, Jordan.
- Laboratory of Nanomedicine, King Abdullah University of Science and Technology, Thuwal, Saudi Arabia.
- Department of Medical Imaging, Faculty of Applied Medical Sciences, The Hashemite University, Zarqa, Jordan.
ORCID-Profile: Dana Alhattab
Förderung
- Scientific Research Fund, Ministry of Higher Education in the Hashemite Kingdom of Jordan
Zitieren
APA
Jamali, F., Aldughmi, M., Atiani, S., Al-Radaideh, A., Dahbour, S., Alhattab, D., Khwaireh, H., Arafat, S., Jaghbeer, J. A., Rahmeh, R., Abu Moshref, K., Bawaneh, H., Hassuneh, M. R., Hourani, B., Ababneh, O., Alghwiri, A., & Awidi, A. (2024). Human Umbilical Cord–Derived Mesenchymal Stem Cells in the Treatment of Multiple Sclerosis Patients: Phase I/II Dose-Finding Clinical Study. Cell Transplantation, 33. https://doi.org/10.1177/09636897241233045
Vancouver
Jamali F, Aldughmi M, Atiani S, Al-Radaideh A, Dahbour S, Alhattab D, et al. Human Umbilical Cord–Derived Mesenchymal Stem Cells in the Treatment of Multiple Sclerosis Patients: Phase I/II Dose-Finding Clinical Study. Cell Transplantation. 2024;33. doi:10.1177/09636897241233045
BibTeX
@article{Jamali2024,
author = {Jamali, Fatima and Aldughmi, Mayis and Atiani, Serin and Al-Radaideh, Ali and Dahbour, Said and Alhattab, Dana and Khwaireh, Hind and Arafat, Sally and Jaghbeer, Joud Al and Rahmeh, Reem and Abu Moshref, Kawthar and Bawaneh, Hisham and Hassuneh, Mona R and Hourani, Bayan and Ababneh, Osameh and Alghwiri, Alia and Awidi, Abdalla},
title = {Human Umbilical Cord–Derived Mesenchymal Stem Cells in the Treatment of Multiple Sclerosis Patients: Phase I/II Dose-Finding Clinical Study},
journal = {Cell Transplantation},
year = {2024},
volume = {33},
doi = {10.1177/09636897241233045}
}
EUVIMED